Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that it has filed a preliminary prospectus supplement to a shelf registration statement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE